Pasithea Reports Phase 1 PAS-004 Data in Four Cancer Patients

Updated data showed prolonged stable disease in four advanced cancer patients, including two treated for more than 500 days. No related serious adverse events, grade 3 or higher treatment-related adverse events, or dose-limiting toxicities were reported; the maximum tolerated dose was not reached, and pharmacokinetic data supported once-daily dosing.